Showing results (111-120 of 261) with videos related to
Sort By:
Pageof 27
The International Journal of Artificial Organs|March 31, 1999
Temporary extracorporeal liver support for severe acute alcoholic hepatitis using the BioLogic-DTA J Ellis, R D Hughes, D Nicholl, et al.American Journal of Medical Genetics. Part A|September 5, 2015
Beyond Ohdo syndrome: A familial missense mutation broadens the MED12 spectrumKatherine G Langley, Jordan Brown, Richard J Gerber, et al.Medical Science Educator|April 6, 2026
Peer-Assisted Learning Improves Confidence and Educational Outcomes: Evidence from a Randomised Control TrialFerdinand J O Boucher, Bella A Magner-Parsons, David MacDonald, et al.The New England Journal of Medicine|February 9, 2007
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasisGerald G Krueger, Richard G Langley, Craig Leonardi, et al.Dermatology and Therapy|December 9, 2017
Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 StudiesDavid Pariser, Ellen Frankel, Joel Schlessinger, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|September 11, 2018
Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trialsR G Langley, A B Kimball, H Nak, et al.The British Journal of Dermatology|February 7, 2018
Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)R G Langley, K Papp, M Gooderham, et al.Neuroimage|July 5, 2008
Volunteer studies in pain research--opportunities and challenges to replace animal experiments: the report and recommendations of a Focus on Alternatives workshopC K Langley, Q Aziz, C Bountra, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 12, 2019
Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasisM Lebwohl, R G Langley, Y Zhu, et al.Journal of the American Academy of Dermatology|July 6, 2010
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendationsMark Lebwohl, Newman Yeilding, Philippe Szapary, et al.Pageof 27